Alcon Inc (ALC)

$87.81 +0.70 (0.80%)
Market Cap 43.31B
Revenue (ttm) 9.91B
Net Income (ttm) 1.02B
EPS (ttm) N/A
PE Ratio 29.04
Forward PE 28.05
Profit Margin 10.27%
Debt to Equity Ratio 0.21
Volume 1,799,600
Avg Vol 1,601,868
Day's Range N/A - N/A
Shares Out 493.24M
Stochastic %K 83%
Beta 0.95
Analysts Strong Sell
Price Target $106.72

Company Profile

Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. It operates through two segments, Surgical and Vision Care. The company offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. Its cataract products include Centurion vision system, LenSx laser system,...

Industry: Medical Instruments & Supplies
Sector: Healthcare
Phone: 41 589 112 110
Address:
Chemin de Blandonnet 8, Vernier, Geneva, Switzerland
ZacksResearch
ZacksResearch May. 29 at 2:55 PM
$ALC gets FDA nod for TRYPTYR — what's the impact? 👀 TRYPTYR, a groundbreaking eye drop for dry eye disease, is set to launch in Q3 2025. This approval is expected to boost Alcon's Vision Care segment. 📈 ALC shares edged up 2.5% in after-market trading after the news, and YTD, ALC’s shares have gained 0.6% against the industry’s 9.1% decline. Discover full insights here 👉 https://www.zacks.com/commentary/2478808/alcon-stock-rises-following-the-fda-approval-of-tryptyr?cid=sm-stocktwits-2-2478808-body&ADID=SYND_STOCKTWITS_TWEET_2_2478808_BODY
0 · Reply
ZacksResearch
ZacksResearch May. 29 at 1:14 PM
FDA approves $ALC's TRYPTYR, a new dry eye treatment with rapid tear production. The approval is supported by strong Phase 3 trial results. Unleash the full story here: https://www.zacks.com/stock/news/2478808/alcon-stock-rises-following-the-fda-approval-of-tryptyr?cid=sm-stocktwits-2-2478808-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2478808_TEASER
0 · Reply
DonCorleone77
DonCorleone77 May. 28 at 8:45 PM
$ALC Alcon's Tryptyr approved by FDA for signs and symptoms of Dry Eye Disease Alcon announced the FDA has approved Tryptyr - acoltremon ophthalmic solution - 0.003%, formerly known as AR-15512, for the treatment of signs and symptoms of Dry Eye Disease. Tryptyr is a first-in-class TRPM8 receptor agonist that stimulates corneal sensory nerves to rapidly increase natural tear production. This approval is supported by two Phase 3 clinical trials evaluating more than 930 patients in which up to four times more Tryptyr patients experienced at least a 10mm increase in natural tear production at Day 14. Tryptyr demonstrated statistically significant natural tear production as early as Day 1. Alcon expects to launch Tryptyr in the U.S. in Q3 2025 and anticipates bringing Tryptyr to other markets in the future.
0 · Reply
EPSMomentumStocks
EPSMomentumStocks May. 28 at 11:39 AM
Projected price trajectory for $ALC over the coming weeks, driven by historical post-earnings announcement drift (PEAD) patterns and momentum trends following its latest earnings release. #stocks #trading #investing
0 · Reply
Estimize
Estimize May. 22 at 8:00 PM
Wall St is expecting 0.72 EPS for $ALC Q2 [Reporting 08/20 AMC] http://www.estimize.com/intro/alc?chart=historical&metric_name=eps&utm_cont
0 · Reply
EPSMomentumStocks
EPSMomentumStocks May. 21 at 11:49 AM
Tracking whether $ALC’s price action remains contained within the projected PEAD cone—a model-based range derived from historical post-earnings behavior, volatility, and market reactions—can offer insights into trend strength, investor sentiment, and potential breakout or mean-reversion scenarios. #stocks #trading #investing
0 · Reply
FractionalShareWhale
FractionalShareWhale May. 14 at 5:13 PM
$ALC raised guidance
0 · Reply
FractionalShareWhale
FractionalShareWhale May. 14 at 3:21 PM
$ALC
0 · Reply
OpenOutcrier
OpenOutcrier May. 14 at 12:58 PM
$ALC (-4.8% pre) Swiss eye care firm Alcon drops after earnings miss, flags tariff impact https://ooc.bz/l/64753
0 · Reply
ZacksResearch
ZacksResearch May. 14 at 11:56 AM
$ALC ends the first quarter of 2025 on a disappointing note. Know more: https://www.zacks.com/stock/news/2470219/alcon-q1-earnings-miss-estimates-stock-down-2025-eps-view-lowered?cid=sm-stocktwits-2-2470219-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2470219_TEASER
0 · Reply
Latest News on ALC
Alcon Canada Earns Global Recognition as a Top Employer

Jun 26, 2025, 9:03 AM EDT - 3 days ago

Alcon Canada Earns Global Recognition as a Top Employer

Gordon Schanzlin New Vision Institute Becomes First U.S. Clinic to Use Alcon's Breakthrough Unity Phaco System

Jun 25, 2025, 10:00 AM EDT - 4 days ago

Gordon Schanzlin New Vision Institute Becomes First U.S. Clinic to Use Alcon's Breakthrough Unity Phaco System

Alcon Introduces Clareon PanOptix Pro in Canada, Delivering the Lowest Light Scatter of any Trifocal IOL

Jun 20, 2025, 9:02 AM EDT - 9 days ago

Alcon Introduces Clareon PanOptix Pro in Canada, Delivering the Lowest Light Scatter of any Trifocal IOL

LENSAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of LENSAR, Inc. - LNSR

Jun 3, 2025, 5:23 PM EDT - 25 days ago

LENSAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of LENSAR, Inc. - LNSR

LNSR

US FDA approves Alcon's new dry-eye drug

May 28, 2025, 5:47 PM EDT - 4 weeks ago

US FDA approves Alcon's new dry-eye drug

Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease

May 28, 2025, 4:40 PM EDT - 4 weeks ago

Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease

Turkey Contact Lens Market - Competition, Forecast & Opportunities to 2030, Featuring Tech Contactlens, Diafarma, Alcon Laboratories, Diplomat Optics, Hoya Turkiye, ZEISS Turkiye, Keralens & more

May 26, 2025, 11:22 AM EDT - 4 weeks ago

Turkey Contact Lens Market - Competition, Forecast & Opportunities to 2030, Featuring Tech Contactlens, Diafarma, Alcon Laboratories, Diplomat Optics, Hoya Turkiye, ZEISS Turkiye, Keralens & more

Alcon Inc. (ALC) Q1 2025 Earnings Call Transcript

May 14, 2025, 12:03 PM EDT - 6 weeks ago

Alcon Inc. (ALC) Q1 2025 Earnings Call Transcript

Alcon, American Eagle, GRAIL And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

May 14, 2025, 8:13 AM EDT - 6 weeks ago

Alcon, American Eagle, GRAIL And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

GRAL

Alcon Reports First-Quarter 2025 Results and Launches Transformational Change in Ophthalmic Surgery with Unity VCS

May 13, 2025, 4:30 PM EDT - 6 weeks ago

Alcon Reports First-Quarter 2025 Results and Launches Transformational Change in Ophthalmic Surgery with Unity VCS

Alcon Announces Results of 2025 Annual General Meeting

May 6, 2025, 4:30 PM EDT - 7 weeks ago

Alcon Announces Results of 2025 Annual General Meeting

Alcon Elevates Vitreoretinal and Cataract Surgery for Superior Efficiency* with UNITY VCS and UNITY CS

Apr 25, 2025, 8:00 AM EDT - 2 months ago

Alcon Elevates Vitreoretinal and Cataract Surgery for Superior Efficiency* with UNITY VCS and UNITY CS

Alcon Publishes Agenda for 2025 Annual General Meeting

Apr 4, 2025, 1:00 AM EDT - 3 months ago

Alcon Publishes Agenda for 2025 Annual General Meeting

Alcon Expands Leadership in IOL Innovation with Clareon PanOptix Pro, Delivering Best-in-Class Light Utilization and Less Light Scatter

Apr 2, 2025, 8:00 AM EDT - 3 months ago

Alcon Expands Leadership in IOL Innovation with Clareon PanOptix Pro, Delivering Best-in-Class Light Utilization and Less Light Scatter

Alcon Acquires Majority Interest in Aurion Biotech, Inc. to Advance Innovative Cell Therapy for Corneal Endothelial Disease

Mar 26, 2025, 4:30 PM EDT - 3 months ago

Alcon Acquires Majority Interest in Aurion Biotech, Inc. to Advance Innovative Cell Therapy for Corneal Endothelial Disease

AURN

Alcon Announces CE Mark Approval and Commercialization of Clareon Vivity IOL in Europe, Expanding Visual Possibilities

Mar 25, 2025, 1:00 AM EDT - 3 months ago

Alcon Announces CE Mark Approval and Commercialization of Clareon Vivity IOL in Europe, Expanding Visual Possibilities

Alcon Agrees to Acquire LENSAR, Inc.

Mar 24, 2025, 8:00 AM EDT - 3 months ago

Alcon Agrees to Acquire LENSAR, Inc.

Retinal Surgery Devices Market Outlook Report 2025-2033: Revenues Set to Double, Reaching $4.83 Billion by 2033, Led by Topcon Corp., Alcon, and Carl Zeiss

Mar 24, 2025, 5:15 AM EDT - 3 months ago

Retinal Surgery Devices Market Outlook Report 2025-2033: Revenues Set to Double, Reaching $4.83 Billion by 2033, Led by Topcon Corp., Alcon, and Carl Zeiss

Alcon to Host 2025 Capital Markets Day

Mar 13, 2025, 9:02 AM EDT - 3 months ago

Alcon to Host 2025 Capital Markets Day

Alcon Canada Strengthens its Commitment to Astigmatic Patients with TOTAL30 for Astigmatism Expanded Parameters

Feb 27, 2025, 9:02 AM EST - 4 months ago

Alcon Canada Strengthens its Commitment to Astigmatic Patients with TOTAL30 for Astigmatism Expanded Parameters

Watch CNBC's full interview with Alcon CEO David Endicott

Feb 26, 2025, 8:54 PM EST - 4 months ago

Watch CNBC's full interview with Alcon CEO David Endicott

Alcon Inc. (ALC) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 11:51 AM EST - 4 months ago

Alcon Inc. (ALC) Q4 2024 Earnings Call Transcript

Alcon eyes revenue growth in 2025 after in-line results

Feb 26, 2025, 2:13 AM EST - 4 months ago

Alcon eyes revenue growth in 2025 after in-line results

Alcon Reports Full-Year 2024 Results, with Strong Top-line and Earnings Growth and Record Cash Generation

Feb 25, 2025, 4:30 PM EST - 4 months ago

Alcon Reports Full-Year 2024 Results, with Strong Top-line and Earnings Growth and Record Cash Generation

Alcon Announces U.S. Launch of New SYSTANE PRO Preservative-Free, Revolutionizing Dry Eye Relief With Its Longest Lasting Formula Yet

Feb 24, 2025, 8:02 AM EST - 4 months ago

Alcon Announces U.S. Launch of New SYSTANE PRO Preservative-Free, Revolutionizing Dry Eye Relief With Its Longest Lasting Formula Yet

Alcon Announces U.S. Launch of Voyager DSLT, First-of-its-Kind Treatment for Glaucoma and Ocular Hypertension

Feb 19, 2025, 8:02 AM EST - 4 months ago

Alcon Announces U.S. Launch of Voyager DSLT, First-of-its-Kind Treatment for Glaucoma and Ocular Hypertension

Alcon to Present at 2025 Annual J.P. Morgan Healthcare Conference

Dec 31, 2024, 4:30 PM EST - 6 months ago

Alcon to Present at 2025 Annual J.P. Morgan Healthcare Conference

Alcon: Q3, Slight Guidance Cut Is Not Something Structural

Nov 14, 2024, 12:17 AM EST - 8 months ago

Alcon: Q3, Slight Guidance Cut Is Not Something Structural

Alcon (ALC) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 12:24 PM EST - 8 months ago

Alcon (ALC) Q3 2024 Earnings Call Transcript

Alcon cuts 2024 forecasts, as slow US hits surgical unit

Nov 13, 2024, 2:17 AM EST - 8 months ago

Alcon cuts 2024 forecasts, as slow US hits surgical unit

Alcon Reports Solid Third-Quarter 2024 Results, including Double-Digit Earnings Growth and Record Cash Generation

Nov 12, 2024, 12:10 PM EST - 8 months ago

Alcon Reports Solid Third-Quarter 2024 Results, including Double-Digit Earnings Growth and Record Cash Generation

Aging population creates opportunity in these healthcare stocks, says Thornburg's Leveille

Oct 15, 2024, 2:04 PM EDT - 9 months ago

Aging population creates opportunity in these healthcare stocks, says Thornburg's Leveille

LLY NVO

Alcon Analysts Increase Their Forecasts After Q2 Results

Aug 22, 2024, 12:00 PM EDT - 11 months ago

Alcon Analysts Increase Their Forecasts After Q2 Results

Alcon CEO: 'Very good' revenue and underlying demand in Q2

Aug 22, 2024, 10:54 AM EDT - 11 months ago

Alcon CEO: 'Very good' revenue and underlying demand in Q2

Alcon Inc. (ALC) Q2 2024 Earnings Call Transcript

Aug 21, 2024, 12:05 PM EDT - 11 months ago

Alcon Inc. (ALC) Q2 2024 Earnings Call Transcript

Alcon Reports Second-Quarter 2024 Results with Strong Growth in Implantables and Contact Lenses

Aug 20, 2024, 4:30 PM EDT - 11 months ago

Alcon Reports Second-Quarter 2024 Results with Strong Growth in Implantables and Contact Lenses

Alcon's Latest Equipment Breakthrough Technologies, Unity VCS and Unity CS, Receive U.S. FDA 510(k) Clearance

Jun 24, 2024, 1:00 AM EDT - 1 year ago

Alcon's Latest Equipment Breakthrough Technologies, Unity VCS and Unity CS, Receive U.S. FDA 510(k) Clearance

Alcon Inc. (ALC) Q1 2024 Earnings Call Transcript

May 14, 2024, 10:48 AM EDT - 1 year ago

Alcon Inc. (ALC) Q1 2024 Earnings Call Transcript

Alcon Reports Strong First-Quarter 2024 Results Driven by Robust Sales in Contact Lenses and Ocular Health

May 13, 2024, 4:30 PM EDT - 1 year ago

Alcon Reports Strong First-Quarter 2024 Results Driven by Robust Sales in Contact Lenses and Ocular Health

Alcon Announces Results of 2024 Annual General Meeting

May 8, 2024, 4:30 PM EDT - 1 year ago

Alcon Announces Results of 2024 Annual General Meeting

Alcon Publishes Agenda for 2024 Annual General Meeting

Apr 7, 2024, 5:59 PM EDT - 1 year ago

Alcon Publishes Agenda for 2024 Annual General Meeting

Vivity, the World's Leading EDOF IOL, Reaches One Million Milestone

Mar 6, 2024, 9:55 AM EST - 1 year ago

Vivity, the World's Leading EDOF IOL, Reaches One Million Milestone

Alcon, Inc. (ALC) Q4 2023 Earnings Call Transcript

Feb 28, 2024, 9:45 PM EST - 1 year ago

Alcon, Inc. (ALC) Q4 2023 Earnings Call Transcript

Alcon's Broad Portfolio Delivers Robust Sales and Earnings Growth in FY 2023

Feb 27, 2024, 4:30 PM EST - 1 year ago

Alcon's Broad Portfolio Delivers Robust Sales and Earnings Growth in FY 2023

Alcon Inc. (ALC) Q3 2023 Earnings Call Transcript

Nov 15, 2023, 11:56 AM EST - 1 year ago

Alcon Inc. (ALC) Q3 2023 Earnings Call Transcript

Alcon's stock falls as third-quarter sales miss estimates

Nov 15, 2023, 8:49 AM EST - 1 year ago

Alcon's stock falls as third-quarter sales miss estimates

Alcon Reports Third Quarter 2023 Results

Nov 14, 2023, 4:30 PM EST - 1 year ago

Alcon Reports Third Quarter 2023 Results

Alcon: Buy An Eyecare Leader With $2 Billion In Quarterly Sales

Oct 10, 2023, 1:03 PM EDT - 1 year ago

Alcon: Buy An Eyecare Leader With $2 Billion In Quarterly Sales

Alcon Inc. (ALC) Q2 2023 Earnings Call Transcript

Aug 16, 2023, 11:29 AM EDT - 2 years ago

Alcon Inc. (ALC) Q2 2023 Earnings Call Transcript

Alcon Reports Second Quarter 2023 Results

Aug 15, 2023, 4:30 PM EDT - 2 years ago

Alcon Reports Second Quarter 2023 Results

ZacksResearch
ZacksResearch May. 29 at 2:55 PM
$ALC gets FDA nod for TRYPTYR — what's the impact? 👀 TRYPTYR, a groundbreaking eye drop for dry eye disease, is set to launch in Q3 2025. This approval is expected to boost Alcon's Vision Care segment. 📈 ALC shares edged up 2.5% in after-market trading after the news, and YTD, ALC’s shares have gained 0.6% against the industry’s 9.1% decline. Discover full insights here 👉 https://www.zacks.com/commentary/2478808/alcon-stock-rises-following-the-fda-approval-of-tryptyr?cid=sm-stocktwits-2-2478808-body&ADID=SYND_STOCKTWITS_TWEET_2_2478808_BODY
0 · Reply
ZacksResearch
ZacksResearch May. 29 at 1:14 PM
FDA approves $ALC's TRYPTYR, a new dry eye treatment with rapid tear production. The approval is supported by strong Phase 3 trial results. Unleash the full story here: https://www.zacks.com/stock/news/2478808/alcon-stock-rises-following-the-fda-approval-of-tryptyr?cid=sm-stocktwits-2-2478808-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2478808_TEASER
0 · Reply
DonCorleone77
DonCorleone77 May. 28 at 8:45 PM
$ALC Alcon's Tryptyr approved by FDA for signs and symptoms of Dry Eye Disease Alcon announced the FDA has approved Tryptyr - acoltremon ophthalmic solution - 0.003%, formerly known as AR-15512, for the treatment of signs and symptoms of Dry Eye Disease. Tryptyr is a first-in-class TRPM8 receptor agonist that stimulates corneal sensory nerves to rapidly increase natural tear production. This approval is supported by two Phase 3 clinical trials evaluating more than 930 patients in which up to four times more Tryptyr patients experienced at least a 10mm increase in natural tear production at Day 14. Tryptyr demonstrated statistically significant natural tear production as early as Day 1. Alcon expects to launch Tryptyr in the U.S. in Q3 2025 and anticipates bringing Tryptyr to other markets in the future.
0 · Reply
EPSMomentumStocks
EPSMomentumStocks May. 28 at 11:39 AM
Projected price trajectory for $ALC over the coming weeks, driven by historical post-earnings announcement drift (PEAD) patterns and momentum trends following its latest earnings release. #stocks #trading #investing
0 · Reply
Estimize
Estimize May. 22 at 8:00 PM
Wall St is expecting 0.72 EPS for $ALC Q2 [Reporting 08/20 AMC] http://www.estimize.com/intro/alc?chart=historical&metric_name=eps&utm_cont
0 · Reply
EPSMomentumStocks
EPSMomentumStocks May. 21 at 11:49 AM
Tracking whether $ALC’s price action remains contained within the projected PEAD cone—a model-based range derived from historical post-earnings behavior, volatility, and market reactions—can offer insights into trend strength, investor sentiment, and potential breakout or mean-reversion scenarios. #stocks #trading #investing
0 · Reply
FractionalShareWhale
FractionalShareWhale May. 14 at 5:13 PM
$ALC raised guidance
0 · Reply
FractionalShareWhale
FractionalShareWhale May. 14 at 3:21 PM
$ALC
0 · Reply
OpenOutcrier
OpenOutcrier May. 14 at 12:58 PM
$ALC (-4.8% pre) Swiss eye care firm Alcon drops after earnings miss, flags tariff impact https://ooc.bz/l/64753
0 · Reply
ZacksResearch
ZacksResearch May. 14 at 11:56 AM
$ALC ends the first quarter of 2025 on a disappointing note. Know more: https://www.zacks.com/stock/news/2470219/alcon-q1-earnings-miss-estimates-stock-down-2025-eps-view-lowered?cid=sm-stocktwits-2-2470219-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2470219_TEASER
0 · Reply
JarvisFlow
JarvisFlow May. 14 at 11:30 AM
Needham updates rating for Alcon ( $ALC ) to Buy, target set at 110.
0 · Reply
Estimize
Estimize May. 13 at 9:45 PM
$ALC reported 0.73 EPS and 2,451 revenue for Q1. http://www.estimize.com/intro/alc?chart=historical&metric_name=eps&utm_content=ALC&utm_med
0 · Reply
Estimize
Estimize May. 12 at 10:00 AM
Wall St is expecting 0.75 EPS for $ALC Q1 [Reporting 05/14 AMC] http://www.estimize.com/intro/alc?chart=historical&metric_name=eps&utm_cont
0 · Reply
AssAndMoney
AssAndMoney May. 5 at 6:03 PM
$ALC calls here
0 · Reply
bravo33
bravo33 Apr. 4 at 1:37 PM
$ALC 90% of their mfg is in Asia and EU, tariff city...
0 · Reply
JarvisFlow
JarvisFlow Mar. 31 at 1:37 PM
Keybanc has updated their rating for Alcon ( $ALC ) to Overweight with a price target of 112.
0 · Reply
JarvisFlow
JarvisFlow Mar. 28 at 1:23 PM
Mizuho has updated their rating for Alcon ( $ALC ) to Outperform with a price target of 120.
0 · Reply
erevnon
erevnon Mar. 28 at 11:54 AM
Needham maintains Alcon $ALC at Buy and raises the price target from $107 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
JarvisFlow
JarvisFlow Mar. 28 at 11:00 AM
Needham updates rating for Alcon ( $ALC ) to Buy, target set at 107 → 110.
0 · Reply
DegenStock
DegenStock Mar. 27 at 2:28 PM
$ALC https://stocks.apple.com/ALTwMXVprRN-ZMno052ce2g
0 · Reply
swingingtech
swingingtech Mar. 25 at 2:49 PM
$COO $ALC https://wallstreetwaves.com/assessing-cooper-companies-stock-how-does-coo-compare-to-healthcare-industry-performance/
0 · Reply
JarvisFlow
JarvisFlow Mar. 20 at 11:00 AM
Needham has updated their rating for Alcon ( $ALC ) to Buy with a price target of 107.
0 · Reply